Smith · Nature medicine 2015 · Animal experimental study and human observational study · n=?

β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis.

Cited 516 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal models and observational human blood measurements (bench/animal research).

PubMed 26147761 · doi:10.1038/nm.3898 · record verified 2026-08-26

What was done

Researchers measured beta-2-microglobulin (B2M) levels in the blood of aging humans and mice, as well as in the hippocampus of aged mice and young mice subjected to heterochronic parabiosis. They evaluated hippocampal neurogenesis and cognitive function in young mice following systemic or local hippocampal administration of exogenous B2M. In addition, they tested whether reducing cell surface MHC I expression (using Tap1-deficient mice) or eliminating endogenous B2M expression in aged knockout mice altered age-related cognitive decline and neurogenesis.

What was found

B2M levels were elevated in the blood of aging humans and mice and increased within the hippocampus of aged mice and young heterochronic parabionts. Systemic or local injection of B2M into young mice impaired hippocampal-dependent cognitive function and neurogenesis. These impairments were partially mitigated in Tap1-deficient mice with reduced cell surface MHC I expression. Aged mice lacking endogenous B2M did not develop age-related cognitive decline and showed enhanced neurogenesis. The abstract reports no numerical values or effect sizes.

Why it matters

This study identifies circulating B2M as a systemic pro-aging factor that directly mediates cognitive impairment and reduced adult neurogenesis via MHC I pathways, presenting a potential molecular target for mitigating age-related neurodegeneration.

Limits

The abstract does not provide sample sizes, effect sizes, statistical confidence intervals, or specific subject demographics for human or mouse cohorts. Interventional findings are derived entirely from mouse models, and the clinical efficacy or safety of targeting B2M in humans was not tested.

Cited by